BIOCORP signs new partnership around Inspair™ with Rx Pack

3rd, February 2022

Issoire (France), February 3rd, 2022, 7:30 am CET – BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, announces today the signature of a new distribution agreement with Rx Pack, a new major player in the design and production of pharmaceutical aerosol delivery devices.

This partnership covers the commercialization of InspairTM, a smart sensor designed by BIOCORP that transforms inhalers into connected devices to help patients suffering from asthma or chronic obstructive pulmonary disease (COPD) in the administration of their treatment. The agreement with RxPack, a 50:50 joint venture between Lindal Group and Coster Group, who have merged their Pharma Operations creating a dedicated new company, will grant them exclusivity in several territories in South America, Eastern Europe, the Middle East and Southeast Asia.


Massimo Carrara, CEO RxPack, stated in a recent declaration: “We are excited to welcome Biocorp among our preferred partners. We believe digital smart delivery enables better patients’ compliance, that is fundamental for good therapy outcomes. Biocorp is a leading company in the field of smartification of pharma delivery systems. We are certain that e-connected devices will lead the way in the Respiratory field in the years to come “.

Eric Dessertenne, CEO of BIOCORP added: We are delighted to be working with Rx Pack to distribute Inspair to a wide range of countries. This is another major marketing agreement for Biocorp, this time for our connected inhaler solution. Chronic respiratory diseases such as asthma and COPD are on the rise worldwide and require more than ever good compliance and monitoring of patients at the risk of seeing their condition worsen dramatically”.

Inspair provides an innovative and effective response to the needs of these two diseases: it directly affects compliance with treatment and strengthens the link between the patient and the medical staff by providing real-time therapeutic monitoring. This smart sensor converts any pressurized metered dose inhaler into a connected device. Inspair records daily inhalation data, monitors proper aerosol preparation (which must be shaken before use), assesses inhalation timing (hand-to-mouth coordination) and provides useful insights into the various stages of inhalation.